Vemurafenib (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vemurafenib" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

4^th place

8^th place

low place

34^th place

8,838^th place

low place

18^th place

31^st place

2^nd place

5^th place

68^th place

28^th place

low place

low place

1web.archive.org

1^st place

2^nd place

low place

low place

doi.org

PDB: 3OG7; Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, in sod. (september 2010). »Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma«. Nature. 467 (7315): 596–599. Bibcode:2010Natur.467..596B. doi:10.1038/nature09454. PMC 2948082. PMID 20823850.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

europa.eu

ema.europa.eu

https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_sl.pdf Povzetek glavnih značilnosti zdravila Zelboraf, vpogled: 5. 1. 2022.

gene.com

»FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer« (tiskovna objava). Genentech. Pridobljeno 17. avgusta 2011.

harvard.edu

ui.adsabs.harvard.edu

PDB: 3OG7; Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, in sod. (september 2010). »Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma«. Nature. 467 (7315): 596–599. Bibcode:2010Natur.467..596B. doi:10.1038/nature09454. PMC 2948082. PMID 20823850.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

nih.gov

ncbi.nlm.nih.gov

PDB: 3OG7; Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, in sod. (september 2010). »Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma«. Nature. 467 (7315): 596–599. Bibcode:2010Natur.467..596B. doi:10.1038/nature09454. PMC 2948082. PMID 20823850.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

pubmed.ncbi.nlm.nih.gov

PDB: 3OG7; Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, in sod. (september 2010). »Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma«. Nature. 467 (7315): 596–599. Bibcode:2010Natur.467..596B. doi:10.1038/nature09454. PMC 2948082. PMID 20823850.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

oncozine.com

Hofland P (20. februar 2012). »First Personalized Cancer Medicine Allows Patients with Deadly Form of Metastatic Melanoma to Live Significantly Longer«. Onco'Zine. The International Cancer Network. Arhivirano iz prvotnega spletišča dne 11. aprila 2012. Pridobljeno 18. februarja 2013. Arhivirano 2012-04-11 na Wayback Machine.

rcsb.org

PDB: 3OG7; Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, in sod. (september 2010). »Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma«. Nature. 467 (7315): 596–599. Bibcode:2010Natur.467..596B. doi:10.1038/nature09454. PMC 2948082. PMID 20823850.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/8320394/vemurafenib?query=vemurafenib&SearchIn=All, vpogled: 5. 1. 2022.

web.archive.org

Hofland P (20. februar 2012). »First Personalized Cancer Medicine Allows Patients with Deadly Form of Metastatic Melanoma to Live Significantly Longer«. Onco'Zine. The International Cancer Network. Arhivirano iz prvotnega spletišča dne 11. aprila 2012. Pridobljeno 18. februarja 2013. Arhivirano 2012-04-11 na Wayback Machine.